AIDS Treatment Goal for Developing Countries Won't Be Met

About 1 million people in the developing world are now getting antiretroviral drugs for AIDS, twice as many as 18 months ago but too few to reach the original goal of treating 3 million people by the end of 2005.

The question becomes, is the glass half full or half empty? Steven Lewis, UN Special Envoy for HIV/AIDS in Africa, clearly believes the primary objectives of the so-called “3 by 5” initiative (3 million people treated by the end of 2005) have been met. Following are his remarks, released today, to a meeting of civil society organizations on the WHO Report on Access to Treatment for AIDS in Africa.

“The report launched today, by WHO and UNAIDS, as a status update on where the world stands in the provision of treatment for AIDS is a predictably fascinating document.

”There will be comments aplenty. I have five.

First, the 3 by 5 initiative seems to me to be entirely vindicated. Mind you, I can even now hear the curmudgeonly bleats of the detractors, whining that we will fall short of the target of three million in treatment by the end of this year.

“Tell that to the million people who are now on treatment and who would otherwise be dead. The truth is that the 3 by 5 initiative which, I predict, will be seen one day as one of the UN's finest hours - has unleashed an irreversible momentum for treatment.

“I see it everywhere as I travel through Africa. Governments are moving heaven and earth to keep
their people alive, and nothing will stop that driving impulse. It is surely noteworthy that 3 by 5 has ushered the phrase "universal treatment" into the language of the pandemic, meaning that we're now all fixated on getting everyone who needs treatment, into treatment, as fast as possible. It
is, I readily admit, both painful and horrifying to see the numbers who are dying as they wait for treatment to be rolled out, but at least there is hope amidst the despair.

Second, it becomes irrefutably clear that treatment has been a boon to prevention. I can recall from many quarters all the caterwauling about the neglect of prevention as the world began to focus on treatment. But the detractors were wrong again. Not only do we continue to emphasize
prevention and reinforce it at country level, but the provision of treatment significantly accelerates testing and counseling, one of the primary ingredients of prevention. Buried in the report, is the astonishing statistic from a study of a district in Uganda, showing a 27-fold increase in counseling and testing as a result of the introduction of treatment!

Third, the G8 certainly has its work cut out for it. What this report appears to do is to throw many of the financial estimates of resource needs for Africa into a cocked hat. WHO and UNAIDS categorically assert that we will need an additional $18 billion dollars, over present commitments, for the three years 2005-2007.

“We know from the recent UNAIDS estimates for 2008, that we will require $22 billion annually, minimum, from that year forward. In the face of these resource imperatives, the idea of doubling foreign aid for Africa by 2010, which would represent another $25 billion per year, is clearly inadequate, some might say paltry.

The $25 billion is supposed to address all of the Millennium Development Goals; it will barely address the one goal of defeating communicable diseases. Unless the G8 can do a lot better than the present calculus, Gleneagles will be much like all the G7/G8 summits before it: a rhetorical triumph, a pragmatic illusion.

Fourth, the report has one particularly evocative diagram. It's a world map portraying the twenty countries with the highest unmet treatment needs, twenty countries where the estimated number of people in treatment is pathetically low. Six of those countries --- South Africa, Zimbabwe,
Tanzania, Nigeria, Ethiopia and India --- represent fully half of the unmet treatment needs. Five of them are in Africa.

“South Africa alone has the largest shortfall in the world, some 866,000 people who should at this very moment be in treatment. The country appears to have something slightly in excess of 100,000 people in treatment, but that represents only 10% to 14% of those who are desperately in need. The numbers for the other African countries, while smaller, are proportionately even more grim. This is where the international community must rally urgent support.

Fifth, the report says, without caveat, that treatment should be provided free at the point where it is given. Finally, we're building a new consensus around the destructive nature of 'user fees', particularly as they prejudice the poor. User fees are a sordid relic of the old economic
conditionalities: it will be excellent to see the end of them.

”It was a good and illuminating report that was released today. It identifies many of the obstacles and bottlenecks, and with spirited intelligence suggests, in each case, a way around them. It's a first-rate blueprint at this point in time.”

07/01/05

Source
S Lewis. UNAIDS Report. June 29, 2005.

Articles on Developing Countries

Heterosexual HIV Epidemic Possible in China - 6/27/05

Immune Reconstitution Disease Is Associated with Mycobacterial Infections in HIV Patients Receiving Antiretrovirals
- 6/08/05

Early Exclusive Breastfeeding Significantly Reduces the Risk of HIV Transmission and Increases HIV-free Survival of Infants  
- 4/11/05

C K Mutuluuza and others.
Short-term Virologic Response to a Triple Nucleoside/Nucleotide Analogue Regimen in Adults with HIV Infection in Africa within the DART Trial. Abstract 22.
- 3/28/05

Global Campaign Against Tuberculosis Makes Headway, but AIDS and Africa Have Big Problems - 3/25/05

Brazil Takes Step Toward Breaking AIDS Patents
- 3/18/05

AIDS Pioneer Luc Montagnier Calls for Focus on 'Therapeutic' Vaccine
- 3/14/05

US Expects to Approve More Generic AIDS Drugs
- 3/07/05

No Benefit Found from GB Virus C (GBV-C) Coinfection in a Cohort of African Women with HIV-1 or HIV-2
- 3/11/05

Very Low Vertical HIV transmission Rates Possible in Africa
- 3/02/05

Prevention of Mother-to-Child Transmission of HIV - 2/28/05

12th Conference on Retroviruses and Opportunistic Infections in Boston: Opening Ceremony and Presentations
- 2/25/05

Incidence of Immune Reconstitution Syndrome in HIV-Tuberculosis Coinfected Patients in India - 2/11/05


Short-course Induction with Boosted Saquinavir Monotherapy for Naive Patients with Late-stage Infection
- 1/28/05

WHO Backs AIDS Drug Nevirapine Despite FDA Warning
- 1/21/05

South Africa Health Officials and Activists Stand by AIDS Drug Nevirapine
- 1/21/05

Risk for Female-to-Male Sexual HIV Transmission May Be Greater Than 2-fold Higher for Uncircumcised Than for Circumcised Men
- 1/21/05

Use of African Herbal Medicines May Result in Bidirectional Drug Interactions and Put Patients at Risk of Treatment Failure, Viral Resistance or Drug Toxicity
- 1/14/05

Large-scale Surveillance for Detecting Transmitted Drug Resistance in Africa is Unnecessary for the Next Decade
- 1/12/05

Implications of the Increased Risk of Tuberculosis (TB) During the Course of HIV Infection
- 1/05/05

Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus 8
- 1/03/05

The Extraordinary Hope of Antiretroviral Therapy in South Africa (Even for Patients with Tuberculosis or Kaposi Sarcoma!)
- 1/03/05

Female Condoms Are Underused in AIDS Prevention - 1/03/05

Enrollment Set to Begin in Studies of Tenofovir as Vaccine to Prevent HIV Infection
- 12/03/04

New Reports, Surveys, Ad Campaigns Released for World AIDS Day
- 12/03/04

Brazil Plans to Break Patents on Foreign AIDS Drugs
- 12/03/04

Bristol-Myers Squibb Sponsors Front Pages of Yahoo Global Websites on World AIDS Day to Raise Awareness of AIDS Crisis - 12/01/04

Rapid HIV Testing Late in Pregnancy Proves Helpful in Peruvian Expectant Mothers
- 11/22/04

Keynote Lectures at the 7th International Congress on Drug Therapy in HIV Infection Held in Glasgow, UK
- 11/19/04

Uganda Opens Africa's Biggest AIDS Training Center
- 10/22/04

Ranbaxy to Resubmit Discontinued AIDS Drugs by Year-end
- 10/20/04

The HIV Netherlands, Australia, Thailand Research Collaboration (HIV-NAT): Lessons from 7 Years of Clinical Research
- 10/18/04

Body Mass Index (BMI) at Time of HIV Diagnosis Is a Strong and Independent Predictor of Survival
 - 10/04/04

Experts Warn of Rising AIDS Stats from East Europe
- 09/20/04

South African Group Demands Info on AIDS Drug Delays
- 09/17/04

Incidence of HIV-1 Dual Infection and Its Association with Increased Viral Load Set Point
 - 09/08/04

AIDS Sharply Cuts Life Expectancy in Mozambique
 - 09/08/04

Zambia Declares AIDS Emergency to Produce Drugs  - 09/08/04

China Bans Blood Trade to Stop AIDS
- 09/01/04

Global AIDS Fund Says US Turns Up Heat on Donors
- 08/23/04

New AIDS Infections in India Could Rise to 5.5 Million Annually  - 08/16/04

WHO Pulls Three Ranbaxy Generics from AIDS Drugs List
 - 08/06/04

Isoniazid Prophylaxis Has an Early and Significant Survival Benefit and Reduces TB in HIV Positive Children in Africa  - 07/21/04

Use of ART in an Active Community-based Cohort in Uganda and Its Impact on HIV-related Mortality  - 07/19/04

Africans Take Anti-HIV Meds at a Higher Rate Than Many Experts Anticipated  - 07/16/04

DART Trial Is Assessing Whether Lab Monitoring Is Necessary for Effective Therapy in Africa, and Whether Treatment Interruptions Can Reduce Toxicity Without Reducing Efficacy - 07/16/04

Maternal and Infant Viral Load Impact Disease Progression in HIV Positive African Infants  - 07/14/04


Developing Nations Expected to Need $20 Billion by 2007  - 07/14/04

New UNAIDS Report Details Latest Global Trends of the AIDS Pandemic: Part II

New UNAIDS Report Details Latest Global Trends of the AIDS Pandemic: Part I


AIDS in India: Nation Could Face Africa-like Disaster  - 07/09/04


Thailand Ttackles Intolerance Ahead of AIDS Meeting
- 07/07/04

Thailand to Deploy 5,000 Police for Global AIDS Meet
- 07/07/04

UNAIDS Says WTO Deal Not Being Implemented
- 07/07/04

Asian AIDS Infections Up as World Response Falters
- 07/07/04

Tanzania Gets Extra $49 M of US Funds for AIDS - 07/02/04

Bush Will Add Vietnam to Global AIDS Initiative
- 06/25/04

Southern Africa Seen in "Death Spiral" on AIDS and Food Shortages - 06/23/04

African Businesses Waking Up to AIDS Threat  - 06/07/04

HHS Proposes Rapid Process For Review of Fixed-dose Combinations and Co-packaged Drug Products  - 05/19/04

India Faces AIDS Tidal Wave, Health Officials Warn 05/12/04

Antiretrovirals from Overseas Meet Content Standards When Stored Properly
04/26/04

Generic and Fixed-dose Drug Combinations for Treatment of HIV/AIDS in Resource-limited Countries
4/19/04

Merck Grants South Africa License for Generic Efavirenz
4/09/04

Clinton and UN Announce Cheap Generic AIDS Drug Plan
4/07/04

Use of Hormonal Contraceptives Increases Female Risk of HIV Infection
3/29/04

US Senators Kennedy and McCain Urge President Bush to Lift Prohibition of US Funds for Purchase of Generic HIV Drugs
3/29/04

Nevirapine- vs Efavirenz-based Therapy in Treatment-naive Indian patients: Comparision of Effectiveness
3/17/04


Glaxo, Boehringer Allow More Generic AIDS Drugs - 12/12/03

 

 

HIV/AIDS Topics
 [ A to Z ]

Abacavir Sensitivity Reaction
Acquired Drug Resistance
Acquired Rectal Fistula

Adherence
Adolescents
African Americans
Age/aging
AIDS-defining Illnesses
AIDS-related Non-Hodgkin's Lymphoma
Alcohol
Alternative Therapies
ALT/AST
Anal Intraepithelial Neoplasia (AIN)
Anemia / Fatigue
Antimycobacterial Prophylaxis
Atheroschlerosis
Aspergillosis
Autoimmune Thyroid Disease
Bacteremia
Bacterial Infections
Bartonella
Body Mass Index (BMI)
Bone Disorders
Boosted Protease Inhibitors
Breast-feeding
Buffalo Hump (BH)
Caesarean section
Candidiasis
Cancers
Cardiovascular Disease
CXCR4 Co-receptor
CCR5 Co-receptor
CD4 T Cell Count/ Percent
CD4+ and CD8 in Whole Blood
CD8+ T Cell
CD8 and CD3 Cells
Cerebrospinal Fluid (CSF)
Cholesterol / Triglycerides
Children and Infants
Central Nervous System (CNS)
Clinical Trials
CMV Retinitis
Complementary Alternative Therapies
Cosmetic Procedures
CYP3A Pathway
Cryptococcus
Cytomegalovirus
Dementia
Depression
Developing Countries
Diabetes
Diarrhea / Gastrointestinal
Dietary Intake
Directly Observed Therapy (DOT)
Disease Progression
Dosing
Drug Abuse
Drug Interactions
Drug Pricing
Drug Resistance Testing
Dyslipidemias
Elevated bilirubin and Jaundice
Elevated Creatinine Level
Entry Inhibitors
Epstein Barr Virus
Epidemiology
Eradication (HIV)
Ethnicity
Experimental Drugs
Experimental Vaccine
Facial Implants
Fat Loss
Fat Accumulation
Fat Redistribution
FDA-Approved Treatments
Fixed-dose Combinations (FDC)
Flu / Fever
Fungal Infections
Fusion or Entry Inhibitors
GB Virus C (GBC of hepatitis G)
Gender
Generics
Genetics
Genotype Resistance Testing
Glucose MetabolismInsulin Resistance
Growth Failure
Growth Hormone
Guidelines
Gynecomastia
HAART / Mega-HAART
Hairy leukoplakia
Hepatotoxicity (Liver Toxicity)
Hispanic Ethnicity
Histoplasmosis
HIV Antibody
HIV Eradication
HIV Prevalence
HIV Proviral DNA Testing
HIV p24 Antigen
HIV-related Adverse Events
HIV Replication
HIV RNA and HIV bDNA Testing
HIV Therapeutics
HIV-1 Fitness Assay
Hodgkin's Disease
Hormone Therapies
Hospice Care
Human Herpesvirus 8 (HHV-8)
Humanpapillomavirus (HPV)
Hydroxyurea (HU)
Hyperlactatemia
Hyperlipidemia
Hypersusceptibility
Hyperbilirubinemia / Jaundice
Hypertension
Hypophosphatemia
Hypothyroidism
Immunotherapy
Immune Based Therapy
Immunosuppression
Immune Restoration Disease
Immune Reconstitution Disease (IRD)
Immune Reconstitution Inflammatory Syndrome (IRIS)
Infants
Infective Endocarditis
Injection Site Reactions
Insulin Resistance
Intensification Therapy
Injection Drug Users (IDU)
Integrase Inhibitors
JC Virus
Kaposi sarcoma
Kidney Toxicity / Failure
Kinetic PCR
Lactic Acidosis/Hyperlactatemia
Liver Enzyme
Kaposi's Sarcoma
Leukoencephalopathy
Lipid Abnormalties
Long-term Non Progression
Lung Diseases
Non-Tuberculosis Lung Diseases
Malignancies
Mega-HAART
Men Who Have Sex with Men (MSM)
Meningoencephalitis
Microbicides
Miscellaneous
Mitochondrial Toxicity
Mortality and Morbidity
Mother-to-Child Transmission
Multidrug Resistant (MDR) HIV
Mutation Resistance
Myalgias (muscle aches)
Mycobacterium avium Complex
Myelopathy
Myocardial Infarction (MI)
Natural History
NAMs
(nucleoside-associated resistance mutations)

Nausea
Neonatal Transmission
Nephrotoxicity
Neopterin
Neurotoxicity
Neutropenia
Nevirapine-associated Rash
Nitazoxanide
Nucleic Acid Screening Test
Non-AIDS Related Hodgkin's Lymphoma
Non-Tuberculosis Lung Diseases
Non-Nucleoside Reverse Transcriptase Inhibitors (nNRTIs)
Non-occupational Post Eexposure Prophylaxis (NPEP)
NNRTI Toxicities and Side Effects Guide
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
Nutrition
Opportunistic Infections (OIs)
Oral OIs/ hairy leukoplakia/ warts
Pain
Palliative Care
Pancreatitis
Parasites
Pathogenesis

Pediatrics
Peripheral Neuropathy
Perinatal Transmission
Pharmacokinetics

Pharmacodynamics
Pneumonia
Pneumocystis carinii pneumonia (PCP)
Phenotype Resistance Testing
Pharmacokinetics
Progressive Multifocal Leukoencephalopathy (PML)
Pheumonia
Physical Exercise
Positron Emission Topography
Protease Assay
Proteinuria and Elevated Creatinine Level
Psychiatric (mental)
PML
Post Exposure Prophylaxis (PEP)

Post-traumatic Stress Disorder (PTSD)
Pregnancy
Prevention
Primary HIV Infection
Protease Inhibitors (PIs) / Boosted PIs
Protease Inhibitor Toxicities/Side Effects (PDF)
Public Policy
Quality of Life

Race / Ethnicity
real-time DNA PCR (RT DNA-PCR)
Renal (Kidney) Toxicity / Failure
Replication Capacity Tests
Resistance
Resistance Mutation
Resistance Testing
Resistance Training
Ritonaivr Boosted PIs
Safer Sex
Salvage Therapies
Seroconversion
Severe Adverse Drug Reactions
Sexual Dysfunction
Sexually Transmitted Diseases
Side Effects
Simplification Regimens/Trials
Skin Conditions
Smoking
Staphylococcus Aureus
Steroids
Stroke
Substance Abuse
Suicidal Ideation
Survival
Super Infection
Sustained Virological Response
Syphilis
Switch Studies
TAMs (thymidine analogue mutations)
Tat gene
Testosterone
thrombosis
Therapeutic Drug Monitoring (TDM)
Therapeutic HIV Vaccines
Thyroid Disease
Toxicities and Side Effects
Toxicities Guides
Toxoplasmosis
Transmission

Transplantation
Treatment Failure
Treatment Guidelines
Treatment Interruptions (TIs)
Tuberculosis
Undetectable HIV Viral Load
Unsafe Sex
Vaccines
Vaginal HIV Shedding
Vertical Transmission of HIV
Viral (HIV) Set Point
Viral Load (HIV RNA or HIV bDNA)
Viral Load Rebound / Increase
Virco Antivirogram
Virologic Control
Virologic Failure
Visceral Adiposity
Virtual Phenotype Resistance Testing
Wasting - HIV
White Race / Caucasian
Women